No Data
Spectral Medical Provides August Tigris Trial Update
Earnings Flash: Spectral Medical Q2 Revenue $471,000 Up From $306,000 in 2023
Spectral Medical Brief: Says Net Proceeds From Offering Expected to Be Primarily Used by the Co on Its Phase III Registration Trial (Tigris) for Its PMX Treatment for Endotoxemic Septic Shock and for General Corporate and Working Capital Purposes
Spectral Medical Inc. Announces Change to Auditor
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
Shareholders May Be More Conservative With Spectral Medical Inc.'s (TSE:EDT) CEO Compensation For Now
No Data